Amneal Pharmaceuticals
AMRX
154 hedge funds and large institutions have $480M invested in Amneal Pharmaceuticals in 2021 Q4 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 55 reducing their positions, and 17 closing their positions.
18% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 17
0.22% more ownership
Funds ownership: 67.24% → 67.46% (+0.22%)
0% more funds holding
Funds holding: 154 → 154 (0)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less capital invested
Capital invested by funds: $535M → $480M (-$55.1M)
18% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 55
64% less call options, than puts
Call options by funds: $1.41M | Put options by funds: $3.88M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$2.17M |
| 2 |
Millennium Management
New York
|
+$1.86M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.57M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$1.22M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$861K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$2.52M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$2.16M |
| 3 |
EP
Eversept Partners
New York
|
-$2.04M |
| 4 |
Prudential Financial
Newark,
New Jersey
|
-$1.83M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$1.83M |
AMRX Hedge Fund Activity: Q4 2021 in Review
154 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2021, worth a combined $480M — down 10% from $535M a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new AMRX positions and 17 closed out — a net gain of 3 holders — while 45 added to existing stakes and 55 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $2.17M. The largest seller was Marshall Wace, exiting entirely with an estimated $2.52M sold.
- 154 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2021, unchanged from Q3 2021.
- Funds reported $480M of Amneal Pharmaceuticals stock for Q4 2021, down 10% quarter-over-quarter.
- 20 funds opened new Amneal Pharmaceuticals positions in Q4 2021 and 17 closed out, a net change of +3 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2021 was Citadel Advisors, an estimated $2.17M added.
- The largest Amneal Pharmaceuticals seller in Q4 2021 was Marshall Wace, an estimated $2.52M sold.
Based on aggregated 13F filings for Q4 2021.